Delivery of compounds for the treatment of headache through an inhalation route
AssigneeAlexza Pharmaceuticals, Inc.
InventorsRon Hale, Joshua Rabinowitz, Dennis Solas, Alejandro Zaffaroni
Life of this patent
Estimating the term…
Abstract
The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.
Claims4
A dose form of sumatriptan comprising a condensation aerosol formed by heating a thin layer containing sumatriptan, on a solid support, to produce a vapor of sumatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% sumatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan.
A dose form of frovatriptan comprising a condensation aerosol formed by heating a thin layer containing frovatriptan, on a solid support, to produce a vapor of frovatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% frovatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan.
A dose form of naratriptan comprising a condensation aerosol formed by heating a thin layer containing naratriptan, on a solid support, to produce a vapor of naratriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% naratriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan.
4-6. (canceled)
Dependencies are inferred from the claim text.